Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Small Cell Lung Carcinoma 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1

Interventions

Cyclophosphamide 27fludarabine phosphate 19Whole-Body Irradiation 18Peripheral Blood Stem Cell Transplantation 18Etoposide 17Rituximab 15Brentuximab Vedotin 15Mycophenolic Acid 14Tacrolimus 13Doxorubicin 12Vincristine 11Prednisone 11Methotrexate 11Busulfan 11Melphalan 9Antilymphocyte Serum 9Cyclosporine 8Filgrastim 6Carboplatin 6Sirolimus 5Radiotherapy 5Lenalidomide 5Gene Expression Profiling 5Cytarabine 5merphos 4Vorinostat 4Immunohistochemistry 4Ifosfamide 4Gemcitabine 4Flow Cytometry 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, Large-Cell, Anaplastic × 7-hydroxystaurosporine × Clear all
NCT00082017 2017-05-15

UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
20 enrolled 13 charts
Lymphoid

Lymphoma, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡